Julien Anract
Overview
Explore the profile of Julien Anract including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Anract J, Pradere B, Pinar U
Curr Opin Urol
. 2024 May;
34(5):384-389.
PMID: 38813704
Purpose Of Review: This review aims to provide an update on the results of studies published in the last two years involving the development of sustainable practices in hospital and...
12.
Baudewyns A, Guenzel K, Halinski A, Dariane C, Delavar G, Anract J, et al.
World J Urol
. 2024 May;
42(1):322.
PMID: 38747982
Purpose: Utility of prostate-specific antigen density (PSAd) for risk-stratification to avoid unnecessary biopsy remains unclear due to the lack of standardization of prostate volume estimation. We evaluated the impact of...
13.
Diamand R, Guenzel K, Mjaess G, Lefebvre Y, Ferriero M, Simone G, et al.
Eur Urol Focus
. 2024 Mar;
10(5):805-811.
PMID: 38508895
Background And Objective: A notable paradigm shift has emerged in the choice of prostate biopsy approach, with a transition from transrectal biopsy (TRBx) to transperineal biopsy (TPBx) driven by the...
14.
Bourgeno H, Jabbour T, Baudewyns A, Lefebvre Y, Ferriero M, Simone G, et al.
Eur Urol Oncol
. 2024 Jan;
7(6):1320-1326.
PMID: 38272745
Background: Systematic biopsy (SB) combined with magnetic resonance imaging (MRI)-targeted biopsy is still recommended considering the risk of missing clinically significant prostate cancer (csPCa). Objective: To evaluate the added value...
15.
Dos Santos L, Carbone F, Pacreau E, Diarra S, Luka M, Pigat N, et al.
Am J Pathol
. 2023 Oct;
194(1):30-51.
PMID: 37827216
Benign prostate hyperplasia (BPH) is caused by the nonmalignant enlargement of the transition zone of the prostate gland, leading to lower urinary tract symptoms. Although current medical treatments are unsatisfactory...
16.
Garrido Castillo L, Anract J, Barry Delongchamps N, Huillard O, BenMohamed F, Decina A, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444476
Prostate cancer is the third cause of cancer-related deaths in men. Its early and reliable diagnosis is still a public health issue, generating many useless prostate biopsies. Prostate cancer cells...
17.
Dariane C, Baures M, Anract J, Barry Delongchamps N, Guidotti J, Goffin V
Med Sci (Paris)
. 2023 May;
39(5):429-436.
PMID: 37219347
Inhibition of androgen signaling is the gold standard treatment of benign prostate hyperplasia and prostate cancer. Despite the initial response to these treatments, therapeutic resistance is ultimately observed in most...
18.
Garrido Castillo L, Mejean A, Vielh P, Anract J, Decina A, Nalpas B, et al.
Life (Basel)
. 2022 Feb;
12(2).
PMID: 35207452
There is an unmet need for reliable biomarkers to predict prostate cancer recurrence after prostatectomy in order to better guide the choice of surgical treatment. We have evaluated the predictive...
19.
Barry Delongchamps N, Schull A, Anract J, Abecassis J, Zerbib M, Sibony M, et al.
PLoS One
. 2021 Jul;
16(7):e0252040.
PMID: 34260598
Objective: To assess the feasibility, safety and precision of organ-based tracking (OBT)-fusion targeted focal microwave ablation (FMA), in patients with low to intermediate risk prostate cancer. Patients And Method: Ten...
20.
Blanc T, Pinar U, Anract J, Assouad J, Audenet F, Borghese B, et al.
J Robot Surg
. 2021 Jan;
15(6):937-944.
PMID: 33511526
The COVID-19 pandemic led to a decrease in surgical activity to avoid nosocomial contamination. Robotic-assisted surgery safety is uncertain, since viral dissemination could be facilitated by gas environment. We assessed...